← Leaderboards
Marcos Javier Ramos-Benitez
U.S. National Inst Allergy & Infect Dis
$1,216,685
Attributed
$1,216,685
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $770.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,216,685 · 2
By mechanism
U54$1,216,685 · 1
FI2$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Symptoms”
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Abraham Aizer Brody · New York University School Of Medicine$25,530,786
- Jennifer Marie Suga · Kaiser Foundation Research Institute$25,200,323
- Rene S. Kahn · Icahn School Of Medicine At Mount Sinai$19,489,320
Research focus
SymptomsExtracellularPhenotypeComplementPlayMediatingMolecularPathway InteractionsSignal PathwayVariantStimulusResponsePathogenesisMonitorAutomobile DrivingAsthmatic PatientAirway EpitheliumAsthma ExacerbationAsthmaAccountingCohortClinically RelevantClinical DataClinical Management
Grant awards (3)
Spleen Tyrosine Kinase Inhibition to target Neutrophil Extracellular Traps in Severe Persistent Asthma$770,202
U54 · FY2025 · MD · contact PI
Spleen Tyrosine Kinase Inhibition to target Neutrophil Extracellular Traps in Severe Persistent Asthma$446,483
U54 · FY2024 · MD · contact PI
Elucidating the Mechanism of Ebola Virus Enterotoxigenicity$0
FI2 · FY2020 · GM · contact PI